Valneva's Pipeline Hopes Hinge on Regulators as Goldman Turns Bearish

Goldman Sachs downgrades Valneva to Sell, but Pfizer backs Lyme vaccine LB6V for 2025 filing; stock down 53% from peak amid legal probe.

The French vaccine developer finds itself caught between a brutal analyst downgrade and the prospect of a regulatory filing that could transform its fortunes. Valneva's stock has been battered to a 12-month low, but the divergence in Wall Street opinion suggests the market is struggling to price in the binary outcome of its lead pipeline asset.

Goldman Sachs delivered the latest blow, slashing its rating on Valneva from "Neutral" to "Sell" and cutting its price target to €2.15. The move sent shares sliding to a fresh yearly trough of $5.25 in US trading. The stock now changes hands at €2.40, representing a roughly 53% collapse from its 52-week peak of €5.16 and a year-to-date decline of nearly 37%.

The investment bank's bearish call stems from a string of setbacks that have eroded confidence in the company's near-term prospects. Beyond the withdrawal of the Chikungunya vaccine Ixchiq, the primary concern centers on the disappointing Phase 3 VALOR trial for the Lyme disease candidate LB6V, developed in partnership with Pfizer.

The Statistical Quagmire

On March 23, Valneva and Pfizer released topline data showing the vaccine had missed its primary endpoint. The culprit was not a lack of efficacy but an unexpectedly low incidence of Lyme disease among trial participants, which robbed the study of statistical power. In a modified intention-to-treat analysis, however, the jab demonstrated 74.8% efficacy with statistical significance — a figure Pfizer has described as clinically meaningful.

The US pharma giant remains committed to the program and intends to submit regulatory applications in both the United States and Europe later this year. For Valneva, a green light would unlock $143 million in milestone payments, tiered royalties between 14% and 22%, and up to $100 million in additional potential payments.

Yet the legal machinery is already grinding into motion. US law firm Pomerantz LLP has launched an investigation into whether Valneva and certain executives misled investors about the trial's prospects. No formal lawsuits have been filed, but the overhang of potential shareholder litigation adds another layer of uncertainty to the stock.

A House Divided

The analyst community is strikingly polarized. Jefferies maintains a "Buy" rating with a $15.00 price target, while Guggenheim also sticks with a buy recommendation at $11.00. The consensus, per MarketBeat, sits at "Hold" with an average target of $11.98 — a far cry from Goldman's €2.15.

The bulls point to the underlying clinical data as evidence that LB6V could still reach the market, and note that Pfizer's continued involvement provides both financial and strategic validation. The bears, led by Goldman, see an uncertain path to approval and a company burning cash at an unsustainable rate.

Valneva's financials paint a mixed picture. The company generated roughly €175 million in revenue in fiscal 2025 and held nearly €110 million in cash at year-end. Management has highlighted improved financial flexibility and a significantly reduced cash burn. But the gross margin remains negative, and the trailing twelve-month EBITDA loss stands at $76 million.

What Comes Next

The immediate catalyst is Valneva's first-quarter earnings report, due on May 7. Guggenheim expects total revenue of €49.1 million, above the FactSet consensus of €45.1 million. The market will scrutinize whether established products Ixiaro and Dukoral can generate enough cash to bridge the gap until a regulatory decision on LB6V.

Beyond the quarterly numbers, the second half of 2026 looms large. Pfizer and Valneva plan to file for approval in the US and Europe, while data from two Phase 2 studies of a Shigella vaccine candidate are also expected. Those milestones will determine whether Valneva's pipeline narrative shifts from one of disappointment to one of renewal — or whether the bears' pessimism proves prescient.